These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38342741)

  • 1. Can NPC1L1 inhibitors reduce the risk of biliary tract cancer? Evidence from a mendelian randomization study.
    Dong H; Chen R; Wang J; Chai N; Linghu E
    Dig Liver Dis; 2024 Sep; 56(9):1599-1604. PubMed ID: 38342741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations of genetically proxied inhibition of HMG-CoA reductase, NPC1L1, and PCSK9 with breast cancer and prostate cancer.
    Sun L; Ding H; Jia Y; Shi M; Guo D; Yang P; Wang Y; Liu F; Zhang Y; Zhu Z
    Breast Cancer Res; 2022 Feb; 24(1):12. PubMed ID: 35151363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic association of lipid-lowering drugs with aortic aneurysms: a Mendelian randomization study.
    Gao X; Luo W; Qu L; Yang M; Chen S; Lei L; Yan S; Liang H; Zhang X; Xiao M; Liao Y; Lee AP; Zhou Z; Chen J; Zhang Q; Wang Y; Xiu J
    Eur J Prev Cardiol; 2024 Jul; 31(9):1132-1140. PubMed ID: 38302118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can Lipid-Lowering Drugs Reduce the Risk of Cholelithiasis? A Mendelian Randomization Study.
    Dong H; Chen R; Xu F; Cheng F
    Clin Epidemiol; 2024; 16():131-141. PubMed ID: 38410417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of genetically proxied lipid-lowering drugs on acute myocardial infarction: a drug-target mendelian randomization study.
    Xiao W; Li Y; Zhuang Z; Song Z; Wang W; Huang N; Dong X; Jia J; Liu Z; Zhao Y; Qi L; Huang T
    Lipids Health Dis; 2024 Jun; 23(1):163. PubMed ID: 38831433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association Between Genetically Proxied Inhibition of HMG-CoA Reductase and Epithelial Ovarian Cancer.
    Yarmolinsky J; Bull CJ; Vincent EE; Robinson J; Walther A; Smith GD; Lewis SJ; Relton CL; Martin RM
    JAMA; 2020 Feb; 323(7):646-655. PubMed ID: 32068819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring the causal effect between lipid-modifying drugs and idiopathic pulmonary fibrosis: a drug-target Mendelian randomization study.
    Cai G; Liu J; Cai M; Shao L
    Lipids Health Dis; 2024 Aug; 23(1):237. PubMed ID: 39090671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mendelian randomization study of circulating lipids and biliary tract cancer among East Asians.
    Wang J; Zhuge J; Feng D; Zhang B; Xu J; Zhao D; Fei Z; Huang X; Shi W
    BMC Cancer; 2022 Mar; 22(1):273. PubMed ID: 35291981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between genetically proxied PCSK9 inhibition and prostate cancer risk: A Mendelian randomisation study.
    Fang S; Yarmolinsky J; Gill D; Bull CJ; Perks CM; ; Davey Smith G; Gaunt TR; Richardson TG
    PLoS Med; 2023 Jan; 20(1):e1003988. PubMed ID: 36595504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of lipid-lowering drug targets with risk of cutaneous melanoma: a mendelian randomization study.
    Miao L; Miao T; Zhang Y; Hao J
    BMC Cancer; 2024 May; 24(1):602. PubMed ID: 38760735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetically proxied therapeutic inhibition of lipid-lowering drug targets and risk of rheumatoid arthritis disease: a Mendelian randomization study.
    Qiao L; Lv S; Meng K; Yang J
    Clin Rheumatol; 2024 Mar; 43(3):939-947. PubMed ID: 38198113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associations between Genetically Proxied Inhibition of Lipid-Lowering Drug Targets and Serum Micronutrients among Individuals of European Descent: A Mendelian Randomization Study.
    He JY; Zhang X; Wang K; Lv WQ
    J Nutr; 2022 May; 152(5):1283-1290. PubMed ID: 35349717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic variation in the cholesterol transporter NPC1L1, ischaemic vascular disease, and gallstone disease.
    Lauridsen BK; Stender S; Frikke-Schmidt R; Nordestgaard BG; Tybjærg-Hansen A
    Eur Heart J; 2015 Jul; 36(25):1601-8. PubMed ID: 25841872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of lipid-lowering drugs with risk of sarcopenia: a drug target mendelian randomization study and meta-analysis.
    Li J; Zang C; Lv H; Xiao Z; Li P; Xiao B; Zhou L
    Hum Genomics; 2024 Jul; 18(1):76. PubMed ID: 38961447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of lipid-lowering drugs with COVID-19 outcomes from a Mendelian randomization study.
    Huang W; Xiao J; Ji J; Chen L
    Elife; 2021 Dec; 10():. PubMed ID: 34866576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 × 2 factorial Mendelian randomization study.
    Ference BA; Majeed F; Penumetcha R; Flack JM; Brook RD
    J Am Coll Cardiol; 2015 Apr; 65(15):1552-61. PubMed ID: 25770315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using genetic variants to evaluate the causal effect of cholesterol lowering on head and neck cancer risk: A Mendelian randomization study.
    Gormley M; Yarmolinsky J; Dudding T; Burrows K; Martin RM; Thomas S; Tyrrell J; Brennan P; Pring M; Boccia S; Olshan AF; Diergaarde B; Hung RJ; Liu G; Legge D; Tajara EH; Severino P; Lacko M; Ness AR; Davey Smith G; Vincent EE; Richmond RC
    PLoS Genet; 2021 Apr; 17(4):e1009525. PubMed ID: 33886544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequence variation in NPC1L1 and association with improved LDL-cholesterol lowering in response to ezetimibe treatment.
    Simon JS; Karnoub MC; Devlin DJ; Arreaza MG; Qiu P; Monks SA; Severino ME; Deutsch P; Palmisano J; Sachs AB; Bayne ML; Plump AS; Schadt EE
    Genomics; 2005 Dec; 86(6):648-56. PubMed ID: 16297596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HMGCR as a promising molecular target for therapeutic intervention in aortic aneurisms: a mendelian randomization study.
    Zheng PF; Zheng ZF; Liu ZY; He J; Rong JJ; Pan HW
    Nutr Metab (Lond); 2024 Oct; 21(1):81. PubMed ID: 39402528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of the NPC1L1 gene and proteome from an exceptional responder to ezetimibe.
    Schweitzer M; Makhoul S; Paliouras M; Beitel LK; Gottlieb B; Trifiro M; Chowdhury SF; Zaman NM; Wang E; Davis H; Chalifour LE
    Atherosclerosis; 2016 Mar; 246():78-86. PubMed ID: 26761771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.